Final analysis of randomized phase II study optimizing melphalan, prednisolone, bortezomib in multiple myeloma (JCOG1105)

CANCER SCIENCE

WILEY

1. National Cancer Center Research and Development Funds [26-A-4, 29-A-3, 2020-J-3, H26-kakushin-teki-gan-ippan-074]
2. Ministry of Health, Labour and Welfare of Japan
3. Japan Agency for Medical Research and Development [JP16ck0106077, JP19ck0106348, 21ck0106685h0001]